BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/18/2022 9:47:46 AM | Browse: 491 | Download: 1509
 |
Received |
|
2021-11-07 14:22 |
|
Peer-Review Started |
|
2021-11-07 14:23 |
|
First Decision by Editorial Office Director |
|
2021-12-12 05:39 |
|
Return for Revision |
|
2021-12-12 05:39 |
|
Revised |
|
2021-12-25 07:07 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-06-24 03:15 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-06-24 22:09 |
|
Articles in Press |
|
2022-06-24 22:09 |
|
Edit the Manuscript by Language Editor |
|
2022-06-19 21:50 |
|
Typeset the Manuscript |
|
2022-07-07 09:19 |
|
Publish the Manuscript Online |
|
2022-07-18 09:47 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Hepatitis B core-related antigen: Are we near a treatment endpoint?
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Tarana Gupta |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Tarana Gupta, Doctor, MBBS, MD, Professor, Medicine, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, House No. 1065 A Sector 1, Rohtak 124001, Haryana, India. taranagupta@gmail.com |
| Key Words |
Hepatitis B core-related antigen; Chronic hepatitis B; Covalently closed circular DNA; Hepatitis B e antigen seroconversion; Hepatitis B virus DNA; Pregenomic RNA |
| Core Tip |
This study highlights the predictive role of hepatitis B core-related antigen (HBcrAg) levels at baseline, and after 24 and 48 wk of antiviral therapy for hepatitis B e antigen seroconversion in chronic hepatitis B patients. The issues related to poor sensitivity of assays and detectable levels in hepatitis B surface antigen-negative patients are major concerns. Future research on the utility of HBcrAg in hepatitis B virus (HBV) flare after nucleotide cessation, occult HBV reactivation, and risk of developing hepatocellular carcinoma is also needed. |
| Publish Date |
2022-07-18 09:47 |
| Citation |
Gupta T. Hepatitis B core-related antigen: Are we near a treatment endpoint? World J Gastroenterol 2022; 28(27): 3532-3534 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i27/3532.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i27.3532 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
